The discovery of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), however, has dramatically changed treatment strategies for EGFR-mutant non-small-cell lung cancer (NSCLC) patients and significantly improved progression-free survival (PFS) and overall survival (OS) compared with conventional chemotherapy.1–4 Likewise, the treatment outcome of BMs from lung cancers has also changed following this paradigm shift. Here, EGFR is linked to non-small cell lung carcinoma.